Medical - Distribution
Build Your Comparison
Side-by-side financial analysisStock Comparison
OMI vs MCK vs JPM vs CAH vs HSIC vs KO
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Distribution
Banks - Diversified
Medical - Distribution
Medical - Distribution
Beverages - Non-Alcoholic
OMI vs MCK vs JPM vs CAH vs HSIC vs KO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||||
|---|---|---|---|---|---|---|
| Industry | Medical - Distribution | Medical - Distribution | Banks - Diversified | Medical - Distribution | Medical - Distribution | Beverages - Non-Alcoholic |
| Market Cap | $171M | $90.23B | $908.57B | $52.19B | $9.17B | $341.71B |
| Revenue (TTM) | $2.76B | $403.43B | $280.33B | $250.55B | $13.18B | $49.28B |
| Net Income (TTM) | $-1.10B | $4.76B | $57.05B | $1.56B | $398M | $13.70B |
| Gross Margin | — | 3.6% | 60.0% | 3.7% | 29.1% | 61.7% |
| Operating Margin | 1.0% | 1.6% | 25.9% | 0.9% | 5.8% | 29.3% |
| Forward P/E | 2.3x | 17.0x | 14.6x | 20.6x | 14.9x | 24.3x |
| Total Debt | $320M | $8.61B | $942.38B | $9.35B | $3.69B | $45.49B |
| Cash & Equiv. | $282M | $3.98B | $343.34B | $3.87B | $156M | $10.27B |
OMI vs MCK vs JPM vs CAH vs HSIC vs KO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jun 20 | Feb 26 | Return |
|---|---|---|---|
| Owens & Minor, Inc. (OMI) | 100 | 29.4 | -70.6% |
| McKesson Corporation (MCK) | 100 | 541.8 | +441.8% |
| JPMorgan Chase & Co. (JPM) | 100 | 325.2 | +225.2% |
| Cardinal Health, In… (CAH) | 100 | 411.7 | +311.7% |
| Henry Schein, Inc. (HSIC) | 100 | 129.3 | +29.3% |
| The Coca-Cola Compa… (KO) | 100 | 167.4 | +67.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: OMI vs MCK vs JPM vs CAH vs HSIC vs KO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
OMI doesn't hold a clear category lead here; it's more of a secondary option in this specific comparison.
MCK is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 12.4%, EPS growth 49.2%, 3Y rev CAGR 13.4%
- 12.4% revenue growth vs OMI's -74.2%
JPM ranks third and is worth considering specifically for long-term compounding and valuation efficiency.
- 481.2% 10Y total return vs MCK's 328.4%
- PEG 0.83 vs HSIC's 4.74
- Lower P/E (14.6x vs 24.3x), PEG 0.83 vs 2.17
CAH is the clearest fit if your priority is momentum.
- +35.3% vs OMI's -70.0%
HSIC is the clearest fit if your priority is sleep-well-at-night and defensive.
- Lower volatility, beta 0.63, Low D/E 76.9%, current ratio 1.38x
- Beta 0.63, current ratio 1.38x
- Beta 0.63 vs OMI's 1.41
KO carries the broadest edge in this set and is the clearest fit for income & stability.
- Dividend streak 56 yrs, beta -0.23, yield 2.6%
- 27.8% margin vs OMI's -39.8%
- 2.6% yield, 56-year raise streak, vs MCK's 0.4%, (2 stocks pay no dividend)
- 13.1% ROA vs OMI's -44.9%, ROIC 15.8% vs 1.8%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 12.4% revenue growth vs OMI's -74.2% | |
| Value | Lower P/E (14.6x vs 24.3x), PEG 0.83 vs 2.17 | |
| Quality / Margins | 27.8% margin vs OMI's -39.8% | |
| Stability / Safety | Beta 0.63 vs OMI's 1.41 | |
| Dividends | 2.6% yield, 56-year raise streak, vs MCK's 0.4%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +35.3% vs OMI's -70.0% | |
| Efficiency (ROA) | 13.1% ROA vs OMI's -44.9%, ROIC 15.8% vs 1.8% |
OMI vs MCK vs JPM vs CAH vs HSIC vs KO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
OMI vs MCK vs JPM vs CAH vs HSIC vs KO — Financial Metrics
Side-by-side numbers across 6 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
KO leads in 2 of 6 categories
OMI leads 1 • CAH leads 1 • MCK leads 0 • JPM leads 0 • HSIC leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
KO leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MCK is the larger business by revenue, generating $403.4B annually — 146.1x OMI's $2.8B. KO is the more profitable business, keeping 27.8% of every revenue dollar as net income compared to OMI's -39.8%. On growth, KO holds the edge at +12.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||||
|---|---|---|---|---|---|---|
| RevenueTrailing 12 months | $2.8B | $403.4B | $280.3B | $250.5B | $13.2B | $49.3B |
| EBITDAEarnings before interest/tax | $277M | $7.1B | $81.4B | $3.2B | $1.1B | $15.5B |
| Net IncomeAfter-tax profit | -$1.1B | $4.8B | $57.0B | $1.6B | $398M | $13.7B |
| Free Cash FlowCash after capex | -$353M | $5.9B | $100.9B | $4.4B | $561M | $12.6B |
| Gross MarginGross profit ÷ Revenue | — | +3.6% | +60.0% | +3.7% | +29.1% | +61.7% |
| Operating MarginEBIT ÷ Revenue | +1.0% | +1.6% | +25.9% | +0.9% | +5.8% | +29.3% |
| Net MarginNet income ÷ Revenue | -39.8% | +1.2% | +20.4% | +0.6% | +3.0% | +27.8% |
| FCF MarginFCF ÷ Revenue | -12.8% | +1.5% | +36.0% | +1.8% | +4.3% | +25.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | -146.3% | +6.0% | — | +11.0% | +7.7% | +12.1% |
| EPS Growth (YoY)Latest quarter vs prior year | +4.5% | +37.0% | +16.0% | -19.5% | +14.9% | +18.2% |
Valuation Metrics
OMI leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 16.2x trailing earnings, JPM trades at a 53% valuation discount to CAH's 34.4x P/E. Adjusting for growth (PEG ratio), JPM offers better value at 0.92x vs HSIC's 7.75x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | ||||||
|---|---|---|---|---|---|---|
| Market CapShares × price | $171M | $90.2B | $908.6B | $52.2B | $9.2B | $341.7B |
| Enterprise ValueMkt cap + debt − cash | $209M | $94.9B | $1.51T | $57.7B | $12.7B | $376.9B |
| Trailing P/EPrice ÷ TTM EPS | -0.16x | 19.56x | 16.22x | 34.38x | 24.44x | 26.12x |
| Forward P/EPrice ÷ next-FY EPS est. | 2.31x | 16.96x | 14.60x | 20.60x | 14.95x | 24.27x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 0.92x | — | 7.75x | 2.34x |
| EV / EBITDAEnterprise value multiple | 1.70x | 13.21x | 18.52x | 18.81x | 11.88x | 25.45x |
| Price / SalesMarket cap ÷ Revenue | 0.06x | 0.22x | 3.25x | 0.23x | 0.70x | 7.13x |
| Price / BookPrice ÷ Book value/share | — | — | 2.51x | — | 2.03x | 9.99x |
| Price / FCFMarket cap ÷ FCF | — | 15.78x | 9.01x | 28.21x | 16.00x | 64.52x |
Profitability & Efficiency
Evenly matched — MCK and KO each lead in 3 of 9 comparable metrics.
Profitability & Efficiency
KO delivers a 41.1% return on equity — every $100 of shareholder capital generates $41 in annual profit, vs $-21 for OMI. HSIC carries lower financial leverage with a 0.77x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), MCK scores 7/9 vs OMI's 2/9, reflecting strong financial health.
| Metric | ||||||
|---|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -21.1% | — | +15.9% | — | +8.2% | +41.1% |
| ROA (TTM)Return on assets | -44.9% | +5.7% | +1.3% | +2.8% | +3.6% | +13.1% |
| ROICReturn on invested capital | +1.8% | +2.5% | +4.5% | +33.8% | +7.1% | +15.8% |
| ROCEReturn on capital employed | +1.3% | +44.8% | +8.9% | +19.2% | +9.8% | +17.3% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 7 | 5 | 6 | 4 | 7 |
| Debt / EquityFinancial leverage | — | — | 2.60x | — | 0.77x | 1.33x |
| Net DebtTotal debt minus cash | $38M | $4.6B | $599.0B | $5.5B | $3.5B | $35.2B |
| Cash & Equiv.Liquid assets | $282M | $4.0B | $343.3B | $3.9B | $156M | $10.3B |
| Total DebtShort + long-term debt | $320M | $8.6B | $942.4B | $9.3B | $3.7B | $45.5B |
| Interest CoverageEBIT ÷ Interest expense | -0.12x | 51.78x | 0.74x | 6.38x | 4.59x | 10.70x |
Total Returns (Dividends Reinvested)
CAH leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CAH five years ago would be worth $41,353 today (with dividends reinvested), compared to $514 for OMI. Over the past 12 months, CAH leads with a +35.3% total return vs OMI's -70.0%. The 3-year compound annual growth rate (CAGR) favors CAH at 35.7% vs OMI's -50.9% — a key indicator of consistent wealth creation.
| Metric | ||||||
|---|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -3.4% | -8.6% | +0.8% | +8.3% | +4.0% | +16.4% |
| 1-Year ReturnPast 12 months | -70.0% | +3.4% | +20.9% | +35.3% | +12.4% | +17.7% |
| 3-Year ReturnCumulative with dividends | -88.2% | +85.0% | +138.8% | +149.7% | +2.6% | +39.3% |
| 5-Year ReturnCumulative with dividends | -94.9% | +312.8% | +135.5% | +313.5% | +6.5% | +65.3% |
| 10-Year ReturnCumulative with dividends | -87.3% | +328.4% | +481.2% | +215.4% | +16.6% | +115.0% |
| CAGR (3Y)Annualised 3-year return | -50.9% | +22.8% | +33.7% | +35.7% | +0.9% | +11.7% |
Risk & Volatility
Evenly matched — JPM and KO each lead in 1 of 2 comparable metrics.
Risk & Volatility
KO is the less volatile stock with a -0.23 beta — it tends to amplify market swings less than OMI's 1.41 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. JPM currently trades 96.2% from its 52-week high vs OMI's 23.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||||
|---|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.41x | -0.11x | 0.87x | -0.05x | 0.63x | -0.23x |
| 52-Week HighHighest price in past year | $9.55 | $999.00 | $338.09 | $233.60 | $89.29 | $84.04 |
| 52-Week LowLowest price in past year | $1.84 | $637.00 | $269.72 | $137.75 | $61.95 | $65.35 |
| % of 52W HighCurrent price vs 52-week peak | +23.5% | +75.1% | +96.2% | +94.9% | +89.5% | +94.5% |
| RSI (14)Momentum oscillator 0–100 | 46.5 | 51.8 | 72.1 | 75.4 | 62.9 | 49.2 |
| Avg Volume (50D)Average daily shares traded | 690K | 906K | 7.4M | 2.0M | 1.4M | 13.6M |
Analyst Outlook
KO leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: OMI as "Hold", MCK as "Buy", JPM as "Buy", CAH as "Buy", HSIC as "Buy", KO as "Buy". Consensus price targets imply 596.4% upside for OMI (target: $16) vs 4.5% for JPM (target: $340). For income investors, KO offers the higher dividend yield at 2.56% vs MCK's 0.41%.
| Metric | ||||||
|---|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $15.60 | $994.86 | $339.75 | $253.38 | $87.43 | $86.13 |
| # AnalystsCovering analysts | 10 | 31 | 61 | 33 | 33 | 48 |
| Dividend YieldAnnual dividend ÷ price | — | +0.4% | +1.8% | +0.9% | — | +2.6% |
| Dividend StreakConsecutive years of raises | 0 | 18 | 15 | 40 | 1 | 56 |
| Dividend / ShareAnnual DPS | — | $3.07 | $5.95 | $2.04 | — | $2.04 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +5.3% | +3.8% | +1.5% | +9.3% | +0.2% |
KO leads in 2 of 6 categories (Income & Cash Flow, Analyst Outlook). OMI leads in 1 (Valuation Metrics). 2 tied.
OMI vs MCK vs JPM vs CAH vs HSIC vs KO: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is OMI or MCK or JPM or CAH or HSIC or KO a better buy right now?
For growth investors, McKesson Corporation (MCK) is the stronger pick with 12.
4% revenue growth year-over-year, versus -74. 2% for Owens & Minor, Inc. (OMI). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 2x trailing P/E (14. 6x forward), making it the more compelling value choice. Analysts rate McKesson Corporation (MCK) a "Buy" — based on 31 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — OMI or MCK or JPM or CAH or HSIC or KO?
On trailing P/E, JPMorgan Chase & Co.
(JPM) is the cheapest at 16. 2x versus Cardinal Health, Inc. at 34. 4x. On forward P/E, Owens & Minor, Inc. is actually cheaper at 2. 3x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 0. 83x versus Henry Schein, Inc. 's 4. 74x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — OMI or MCK or JPM or CAH or HSIC or KO?
Over the past 5 years, Cardinal Health, Inc.
(CAH) delivered a total return of +313. 5%, compared to -94. 9% for Owens & Minor, Inc. (OMI). Over 10 years, the gap is even starker: JPM returned +481. 2% versus OMI's -87. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — OMI or MCK or JPM or CAH or HSIC or KO?
By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.
23β versus Owens & Minor, Inc. 's 1. 41β — meaning OMI is approximately -705% more volatile than KO relative to the S&P 500. On balance sheet safety, Henry Schein, Inc. (HSIC) carries a lower debt/equity ratio of 77% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.
05Which is growing faster — OMI or MCK or JPM or CAH or HSIC or KO?
By revenue growth (latest reported year), McKesson Corporation (MCK) is pulling ahead at 12.
4% versus -74. 2% for Owens & Minor, Inc. (OMI). On earnings-per-share growth, the picture is similar: Cardinal Health, Inc. grew EPS 87. 0% year-over-year, compared to -201. 1% for Owens & Minor, Inc.. Over a 3-year CAGR, MCK leads at 13. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — OMI or MCK or JPM or CAH or HSIC or KO?
The Coca-Cola Company (KO) is the more profitable company, earning 27.
3% net margin versus -39. 8% for Owens & Minor, Inc. — meaning it keeps 27. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KO leads at 28. 7% versus 1. 0% for OMI. At the gross margin level — before operating expenses — KO leads at 61. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is OMI or MCK or JPM or CAH or HSIC or KO more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 0. 83x versus Henry Schein, Inc. 's 4. 74x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Owens & Minor, Inc. (OMI) trades at 2. 3x forward P/E versus 24. 3x for The Coca-Cola Company — 22. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for OMI: 596. 4% to $15. 60.
08Which pays a better dividend — OMI or MCK or JPM or CAH or HSIC or KO?
In this comparison, KO (2.
6% yield), JPM (1. 8% yield), CAH (0. 9% yield), MCK (0. 4% yield) pay a dividend. OMI, HSIC do not pay a meaningful dividend and should not be held primarily for income.
09Is OMI or MCK or JPM or CAH or HSIC or KO better for a retirement portfolio?
For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.
23), 2. 6% yield, +115. 0% 10Y return). Both have compounded well over 10 years (KO: +115. 0%, OMI: -87. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between OMI and MCK and JPM and CAH and HSIC and KO?
These companies operate in different sectors (OMI (Healthcare) and MCK (Healthcare) and JPM (Financial Services) and CAH (Healthcare) and HSIC (Healthcare) and KO (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: OMI is a small-cap quality compounder stock; MCK is a mid-cap quality compounder stock; JPM is a large-cap deep-value stock; CAH is a mid-cap quality compounder stock; HSIC is a small-cap quality compounder stock; KO is a large-cap quality compounder stock. JPM, CAH, KO pay a dividend while OMI, MCK, HSIC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.